肠道微生物群和血液代谢物与儿童肥胖之间的因果关系:孟德尔的随机化研究

Ji-Gan Wang1, Xiu-Hua Pan2, Yan Li2

  • 1Department of Pediatrics, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region; Guangxi Clinical Research Center for Pediatric Diseases, Nanning, China. wangjigan@163.com.

Pediatric research
|September 25, 2025
PubMed
概括

这项研究揭示了特定的肠道细菌和血液代谢产物与儿童肥胖有因果关系. 一些细菌和代谢产物可以防止肥胖,而另一些则会增加风险,提供新的干预目标.

相关概念视频

Anatomy of the Intestines01:23

Anatomy of the Intestines

Although digestion of proteins, carbohydrates, and lipids may begin in the stomach, it is completed in the intestine. The absorption of nutrients, water, and electrolytes from food and drink also occurs in the intestine. The intestines can be divided into two structurally distinct organs—the small and large intestines.
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
86.8K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
247
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169